A detailed history of Federated Hermes, Inc. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 1,663,900 shares of RYTM stock, worth $92.9 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
1,663,900
Previous 1,660,784 0.19%
Holding current value
$92.9 Million
Previous $68.2 Million 27.83%
% of portfolio
0.2%
Previous 0.17%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$40.81 - $55.0 $127,163 - $171,380
3,116 Added 0.19%
1,663,900 $87.2 Million
Q2 2024

Aug 08, 2024

SELL
$35.41 - $44.37 $11,083 - $13,887
-313 Reduced 0.02%
1,660,784 $68.2 Million
Q1 2024

May 14, 2024

SELL
$39.12 - $52.44 $25.4 Million - $34.1 Million
-649,858 Reduced 28.12%
1,661,097 $72 Million
Q4 2023

Jan 31, 2024

SELL
$21.39 - $49.64 $649,828 - $1.51 Million
-30,380 Reduced 1.3%
2,310,955 $106 Million
Q3 2023

Nov 13, 2023

SELL
$15.81 - $27.8 $24.5 Million - $43.1 Million
-1,550,348 Reduced 39.84%
2,341,335 $53.7 Million
Q1 2023

May 08, 2023

SELL
$16.88 - $34.24 $40.7 Million - $82.6 Million
-2,412,799 Reduced 38.27%
3,891,683 $69.4 Million
Q4 2022

Feb 13, 2023

SELL
$22.21 - $30.25 $52,948 - $72,116
-2,384 Reduced 0.04%
6,304,482 $184 Million
Q3 2022

Nov 14, 2022

BUY
$4.3 - $30.85 $8.22 Million - $59 Million
1,911,266 Added 43.48%
6,306,866 $155 Million
Q2 2022

Aug 15, 2022

SELL
$3.12 - $12.25 $2.09 Million - $8.2 Million
-669,513 Reduced 13.22%
4,395,600 $18.2 Million
Q1 2022

May 13, 2022

BUY
$6.13 - $12.24 $13.9 Million - $27.7 Million
2,261,778 Added 80.68%
5,065,113 $58.4 Million
Q4 2021

Feb 14, 2022

SELL
$8.62 - $13.9 $1.79 Million - $2.89 Million
-207,718 Reduced 6.9%
2,803,335 $28 Million
Q3 2021

Nov 15, 2021

SELL
$11.68 - $20.72 $48,565 - $86,153
-4,158 Reduced 0.14%
3,011,053 $39.3 Million
Q2 2021

Aug 16, 2021

SELL
$18.52 - $22.55 $1.77 Million - $2.16 Million
-95,642 Reduced 3.07%
3,015,211 $59 Million
Q1 2021

May 13, 2021

BUY
$20.25 - $39.49 $9.99 Million - $19.5 Million
493,253 Added 18.84%
3,110,853 $66.2 Million
Q4 2020

Feb 12, 2021

BUY
$21.17 - $32.61 $7.41 Million - $11.4 Million
350,000 Added 15.43%
2,617,600 $77.8 Million
Q3 2020

Nov 12, 2020

BUY
$18.13 - $30.61 $27,720 - $46,802
1,529 Added 0.07%
2,267,600 $49.1 Million
Q2 2020

Aug 13, 2020

BUY
$14.41 - $25.35 $2,464 - $4,334
171 Added 0.01%
2,266,071 $50.5 Million
Q1 2020

May 13, 2020

BUY
$13.16 - $22.9 $1.42 Million - $2.47 Million
107,881 Added 5.0%
2,265,900 $34.5 Million
Q4 2019

Feb 14, 2020

BUY
$19.53 - $25.5 $13.5 Million - $17.7 Million
692,619 Added 47.26%
2,158,019 $49.5 Million
Q3 2019

Nov 14, 2019

BUY
$18.62 - $24.51 $10.7 Million - $14 Million
573,200 Added 64.25%
1,465,400 $31.6 Million
Q1 2019

May 10, 2019

SELL
$24.76 - $31.66 $25,849 - $33,053
-1,044 Reduced 0.12%
892,200 $24.5 Million
Q4 2018

Feb 13, 2019

BUY
$24.11 - $31.34 $2.48 Million - $3.22 Million
102,823 Added 13.01%
893,244 $24 Million
Q3 2018

Nov 13, 2018

BUY
$26.99 - $35.85 $14.6 Million - $19.4 Million
540,421 Added 216.17%
790,421 $23.1 Million
Q2 2018

Aug 10, 2018

BUY
$17.02 - $35.2 $1.7 Million - $3.52 Million
100,000 Added 66.67%
250,000 $7.82 Million
Q4 2017

Feb 28, 2018

BUY
$22.0 - $30.51 $3.3 Million - $4.58 Million
150,000
150,000 $4.36 Million

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.11B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.